Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24601367 | 1.00 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 | |
| SCHEMBL29073847 | 1.00 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 | |
| SCHEMBL29073850 | 1.00 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 | |
| SCHEMBL29762311 | 0.92 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL29073477 | 0.92 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL29073483 | 0.92 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL26628399 | 0.92 | ADORA3 (0.65) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL29073789 | 0.87 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 | |
| SCHEMBL29762121 | 0.87 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 | |
| SCHEMBL24600612 | 0.87 | ADORA3 (0.62) | ADORA3ADORA1ADORA2AADORA2BHSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783196-A | A3 adenosine receptor agonists, methods of making and uses thereof | 浙江春禾医药科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2022143740-A1 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江春禾医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885ADORA1 4/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.